Use of the activated partial thromboplastin time for heparin monitoring. 2001

M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, MI, USA.

The objectives of the present study were to evaluate the relationship between heparin concentration and activated partial thromboplastin time (aPTT) results, define a heparin concentration-derived therapeutic range for each aPTT instrument, compare aPTT- and heparin concentration-guided dosage adjustment decisions, and compare laboratory- and bedside aPTT-guided decisions. In phase 1, 102 blood samples were analyzed for bedside and laboratory aPTTs and heparin concentration (used to establish aPTT therapeutic range). In phase 2, 100 samples were analyzed in the same manner. Correlations for aPTT compared with heparin ranged from 0.36 to 0.82. Dosage adjustment decisions guided by the aPTT agreed with those based on heparin concentration 63% to 80% of the time. Laboratory and bedside aPTT dosage adjustment decisions agreed 59% to 68% of the time. The correlation of aPTT with heparin concentration and agreement between aPTT- and heparin-guided decisions vary with the aPTT instrument. Decisions guided by laboratory aPTT results often disagree with decisions guided by bedside aPTT results.

UI MeSH Term Description Entries
D007753 Laboratories Facilities equipped to carry out investigative procedures. Laboratory
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
March 1971, Canadian Medical Association journal,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
October 1995, The Annals of pharmacotherapy,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
June 2003, Artificial organs,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
January 1989, La Ricerca in clinica e in laboratorio,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
May 1980, World journal of surgery,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
November 1993, The Canadian journal of cardiology,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
April 1979, American journal of clinical pathology,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
April 1999, Pharmacotherapy,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
June 2012, Pharmacotherapy,
M A Smythe, and J M Koerber, and S J Westley, and S N Nowak, and R L Begle, and M Balasubramaniam, and J C Mattson
January 1981, Journal of clinical pathology,
Copied contents to your clipboard!